Press release
Hypertriglyceridemia Treatment Market Accelerates as APOC3 and ANGPTL3 Inhibitors Redefine Cardiometabolic Care
Hypertriglyceridemia Treatment Market
The Global Hypertriglyceridemia Treatment Market is expected to reach at a significant CAGR during the forecast period 2024-2031.
DataM Intelligence has published a new research report on "Hypertriglyceridemia Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/hypertriglyceridemia-treatment-market?rk
Recent Developments:
✅ October 2025: A leading biopharmaceutical company announced positive Phase III trial results for a next-generation APOC3 inhibitor designed to significantly reduce triglyceride levels in patients with severe hypertriglyceridemia. The therapy demonstrated substantial triglyceride lowering beyond 70%, positioning it as a promising option for patients at high risk of pancreatitis and cardiovascular complications.
✅ August 2025: Amarin Corporation expanded its cardiovascular outcomes data for its omega-3-based therapy, highlighting its role in reducing residual cardiovascular risk among patients with elevated triglycerides despite statin therapy. The update reinforced the importance of triglyceride management as part of comprehensive lipid control strategies.
✅ June 2025: Ionis Pharmaceuticals reported progress in advancing antisense therapies targeting ANGPTL3 for patients with genetic lipid disorders and refractory hypertriglyceridemia. The company emphasized the growing clinical focus on precision medicine approaches in lipid metabolism disorders.
✅ April 2025: Pfizer Inc. initiated new combination therapy trials evaluating lipid-lowering agents targeting triglycerides alongside LDL cholesterol management, reflecting a broader shift toward integrated dyslipidemia treatment models.
Mergers & Acquisitions:
✅ November 2025: AstraZeneca plc acquired a clinical-stage biotech specializing in lipid metabolism therapeutics to strengthen its cardiovascular and metabolic disease portfolio, expanding its pipeline of triglyceride-lowering drug candidates.
✅ September 2025: Novartis AG completed the acquisition of a gene-silencing technology firm focused on RNA-based therapies for rare lipid disorders, enhancing its capabilities in advanced hypertriglyceridemia treatments.
✅ July 2025: Eli Lilly and Company finalized a strategic acquisition of a metabolic disease biotech company developing next-generation lipid-regulating agents, reinforcing its presence in cardiometabolic therapeutics.
✅ May 2025: Merck & Co., Inc. invested in a digital health startup specializing in lipid monitoring and cardiovascular risk analytics, enabling enhanced patient management solutions integrated with pharmacological hypertriglyceridemia therapies.
Key Players:
Hikma Pharmaceuticals PLC, Woodward Pharma Services LLC, AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Ionis Pharmaceuticals Inc., Mylan N.V., Accord Healthcare, Sun Pharmaceutical Industries Limited, and Amryt Pharma plc.
Growth Forecast Projected:
The Global Hypertriglyceridemia Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Hypertriglyceridemia Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=hypertriglyceridemia-treatment-market?rk
Key Segments:
By Drug Class: Fibrates, Omega-3 Fatty Acids, Statins, Others.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.
Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.
Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.
Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.
Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.
Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.
Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.
Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.
Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/hypertriglyceridemia-treatment-market?rk
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?rk
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?rk
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertriglyceridemia Treatment Market Accelerates as APOC3 and ANGPTL3 Inhibitors Redefine Cardiometabolic Care here
News-ID: 4402512 • Views: …
More Releases from DataM Intelligence 4market Research LLP
Shale Gas Market to Reach US$ 728 Billion by 2030 at 4.8% CAGR, Driven by Advanc …
The Shale Gas Market reached approximately US$ 558 billion in 2024 and is expected to grow to around US$ 728 billion by 2030, expanding at a CAGR of about 4.8% from 2025 to 2030 as global energy markets continue to balance supply security, cost competitiveness, and the transition toward cleaner fuels.
Growth is supported by increasing demand across key applications such as power generation, industrial fuel use, residential and commercial heating,…
Animal Stem Cell Therapy Market to Expand at 5% CAGR by 2031, Driven by MSC-Base …
The Animal Stem Cell Therapy Market is expected to grow at a CAGR of 5% from 2024 to 2031. as veterinary healthcare providers and pet owners increasingly adopt regenerative medicine solutions to treat musculoskeletal, orthopedic, and chronic conditions in companion and performance animals.
Growth is supported by rising demand across key therapy areas such as osteoarthritis, tendon and ligament injuries, and wound healing, driven by the need for minimally invasive,…
Breast Cancer Liquid Biopsy Market to Reach US$7.98 Billion by 2031 at 23.2% CAG …
The Breast Cancer Liquid Biopsy Market reached US$ 1.6 billion in 2023 and is expected to reach US$ 7.98 billion by 2031, growing at a CAGR of 23.2% from 2024 to 2031 as demand for non‐invasive cancer diagnostics and real‐time treatment monitoring accelerates globally.
Growth is supported by rising demand across key product segments such as reagents & kits and instruments, driven by increasing prevalence of breast cancer, technological advancements in…
United States Healthcare Staffing Market Expands Amid Physician Shortages, Teleh …
Healthcare Staffing Market is valued at a significant CAGR during the forecast period (2024-2031). As per DataM Intelligence Database.
The Healthcare Staffing market is dominated by large-scale staffing and workforce solutions providers such as Envision Healthcare, AMN Healthcare, CHG Management, Cross Country Healthcare, and Maxim Healthcare Group, all specializing in nurse and allied healthcare placement. Aya Healthcare, TeamHealth, and Trustaff stand out for their agile travel nurse and locum tenens programs.…
More Releases for Hypertriglyceridemia
Hypertriglyceridemia Market to Reach USD 23.94 Billion by 2034
Pune, India - December 2025 - The global Hypertriglyceridemia Market, valued at USD 13.12 billion in 2024, is projected to reach USD 23.94 billion by 2034, growing at a 6.1% CAGR (2025-2034), according to Exactitude Consultancy. Rising prevalence of obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease is driving strong demand for triglyceride-lowering therapies worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72029
Market Summary
The Hypertriglyceridemia Market is expanding…
Severe Hypertriglyceridemia Market to Reach USD 5.42 Billion by 2034
Pune, India - December 2025 - The global Severe Hypertriglyceridemia (SHTG) Market, valued at USD 3.07 billion in 2024, is projected to reach USD 5.42 billion by 2034, growing at a 5.7% CAGR (2025-2034), according to Exactitude Consultancy. The increasing prevalence of obesity, diabetes, metabolic syndrome, and cardiovascular diseases is driving strong demand for advanced triglyceride-lowering treatments.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72003
Market Summary
The Severe Hypertriglyceridemia Market…
Hypertriglyceridemia Market is expected to reach USD 39 billion by 2034
Hypertriglyceridemia is a common lipid disorder characterized by elevated levels of triglycerides in the blood, often associated with obesity, diabetes, metabolic syndrome, and genetic predisposition. While mild to moderate hypertriglyceridemia is widespread, severe cases can lead to acute pancreatitis, cardiovascular disease, and liver complications. The condition is both a standalone metabolic issue and a risk factor for a broader spectrum of chronic diseases.
Download Full PDF Sample Copy of Market Report…
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe…
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
